In a reversal about what the public health officials and scientists have been telling us for months, Dr. Mike Yeadon, the former Chief Science Officer for the pharmaceutical giant Pfizer says “there is no science to suggest a second wave should happen.” Dr. Yeadon said that false-positive results from inherently unreliable COVID tests are being used to manufacture a “second wave” based on “new cases.”
With a degree in biochemistry and toxicology and a research-based Ph.D. in respiratory pharmacology, Dr. Mike Yeadonhas spent over 30 years leading new medicines research in some of the world’s largest pharmaceutical companies. He worked for Pfizer for 16 years before in 2011 as Vice President & Chief Scientist for Allergy & Respiratory. Since leaving Pfizer, Dr. Yeadon has founded his own biotech company, Ziarco, which was sold to the world’s biggest drug company, Novartis, in 2017.
In an interview with Julia Hartley-Brewer, Dr. Yeadon said the Government is “using a test with an undeclared false positive rate.” He said that he wants those who have tested positive for coronavirus to be tested again to eliminate the possibility of the test being a false positive.
Even if all positives were to be correct, Dr. Yeadon explained that given the “shape” of all important indicators in a worldwide pandemic, such as hospitalizations, ICU utilization, and deaths, “the pandemic is fundamentally over.”
“Were it not for the test data that you get from the TV all the time, you would rightly conclude that the pandemic was over, as nothing much has happened. Of course people go to the hospital, moving into the autumn flu season…but there is no science to suggest a second wave should happen,” Yeadon said in the interview.
You can watch the video of his interview below.
Back in September, Dr. Yeadon also co-authored a paper with two of his colleagues. In the paper, which is titled: “How Likely is a Second wave?” they explained:
“It has widely been observed that in all heavily infected countries in Europe and several of the US states likewise, that the shape of the daily deaths vs. time curves is similar to ours in the UK. Many of these curves are not just similar, but almost super imposable.”
Dr. Yeadon and the two scientists also looked at the national weekly mortality data from the UK to see the effect of the COVID-19 pandemic. They used the data of the past four years for comparison purposes and to calculate upper and lower control limits (based on two standard deviations).
Below is how they described their findings:
This shows that in the pandemic peak (April 17th to 30th) more than twice the number of seasonal average deaths occurred, with the number of deaths above the upper control limit from March 27th through to June 12th, totalling 44,895 excess deaths. Since June 26th the number of weekly deaths has now fallen so it is not only below the weekly average but has regularly dropped below the lower control limit, showing that we are now at the lowest number of weekly deaths recorded in many years.
Based on their study, they found that “over the last three months since lockdown measures started easing on the May 10th there has been no increase in weekly deaths. On the contrary, these have continued to fall.”
Dr. Yeadon further pointed out that the “novel” COVID-19 contagion is novel only in the sense that it is a new type of coronavirus. But, he said, there are presently four strains which circulate freely throughout the population, most often linked to the common cold.
Yeadon et al added:
“There are at least four well characterised family members (229E, NL63, OC43 and HKU1) which are endemic and cause some of the common colds we experience, especially in winter. They all have striking sequence similarity to the new coronavirus.”
Toward the end of the paper, Dr. Yeadon and the two other scientists also addressed the sudden surge in coronavirus cases and what is happening in terms of second wave concerns in France and Spain. They “contend that the many claims in the media for outbreaks, spikes and second waves are all artefacts of amplified rates of testing.”
“It should be noted that illness, hospitalisations and deaths have not reversed in any clear and sustained manner. Specifically, careful examination of the weekly all-causes mortality data in France is completely clear. Six weeks into an apparent surge of cases, the number of deaths remain completely flat and normal, in all age bands (as of mid-August when this document was written).”
The authors concluded with recent charts of daily cases from the two countries to further support their claim that the second wave is over.
R
